Mike Crapo

I encourage you to recognize that Congress has the authority to make this determination.

Some want the IRS to prepare tax returns for taxpayers, and several colleagues have actually introduced legislation in Congress to authorize the IRS to do that.

I hope you will continue to be transparent, accessible, and willing to work with me and my colleagues.

I hope you will continue to be transparent, accessible, and willing to work with me and my colleagues.

I was very interested in your, again, making the pledge that you will not increase audits on those making less than $400,000.

I encourage you to recognize that Congress has the authority to make this determination.

Some want the IRS to prepare tax returns for taxpayers, and several colleagues have actually introduced legislation in Congress to authorize the IRS to do that.

How well you adhere to these promises will determine the legacy you leave the IRS and the American taxpayers with.

I strongly suggest you accelerate your timeline and return to this committee in short order with an actual plan.

I hope you will continue to be transparent, accessible, and willing to work with me and my colleagues.

I hope you will continue to be transparent, accessible, and willing to work with me and my colleagues.

I was very interested in your, again, making the pledge that you will not increase audits on those making less than $400,000.

Some want the IRS to prepare tax returns for taxpayers, and several colleagues have actually introduced legislation in Congress to authorize the IRS to do that.

I encourage you to recognize that Congress has the authority to make this determination.

We appreciate this hearing's focus on examining the role that pharmacy benefit managers (PBMs) play in the American healthcare system.

We need to identify avenues for lowering out-of-pocket costs, increasing competition, and promoting access to lifesaving innovation--and we need to do so in a fiscally responsible manner.

In many ways, Medicare Part D reflects an unprecedented success story, coming in massively under budget, with low and stable monthly premiums--and with a generic drug dispensing rate of roughly 90 percent.

That said, much has changed in the past 2 decades, and we have an obligation both to build on the aspects of Part D that work well and to address access and affordability gaps where we find them.

Today, I am introducing legislation called the Lower Drug Costs for Families Act, and what it will do is penalize pharmaceutical companies for increasing the price of their drugs faster than the rate of inflation.

Obviously, transparency is key.

We have got to figure out how to strengthen Medicare.

We have to change that.

When we talk about the need for greater transparency in the drug supply chain, that term can and should mean a few different things.

I have long championed efforts to improve prescription drug access and affordability for all Americans.

Some of the most lifesaving medications remain out of reach for far too many working families and seniors.